Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control (Q42802278)

7 November 2017

title

Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control (English)

1 reference

7 November 2017

0 references

1 reference

M Nakata

1

1 reference

7 November 2017

S Nagasaka

2

1 reference

7 November 2017

I Kusaka

3

1 reference

7 November 2017

H Matsuoka

4

1 reference

7 November 2017

S Ishibashi

5

1 reference

7 November 2017

T Yada

6

1 reference

7 November 2017

publication date

10 May 2006

1 reference

7 November 2017

1 reference

7 November 2017

volume

49

1 reference

7 November 2017

issue

8

1 reference

7 November 2017

page(s)

1881-1892

1 reference

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00125-006-0269-5

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-006-0269-5

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-006-0269-5

Role of caveolin and caveolae in insulin signaling and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-006-0269-5

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00125-006-0269-5

21 January 2018

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

1 reference

12 December 2020

Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes

1 reference

12 December 2020

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

1 reference

12 December 2020

Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways

1 reference

12 December 2020

Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells

1 reference

12 December 2020

Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells

1 reference

12 December 2020

The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes

1 reference

12 December 2020

CCAAT/enhancer binding protein alpha maintains the ability of insulin-stimulated GLUT4 translocation in 3T3-C2 fibroblastic cells.

1 reference

12 December 2020

Importance of adipocytokines in obesity-related diseases

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

1 reference

12 December 2020

The NSY mouse: a new animal model of spontaneous NIDDM with moderate obesity.

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity.

1 reference

12 December 2020

Measurement of glucose uptake and intracellular calcium concentration in single, living pancreatic beta-cells

1 reference

12 December 2020

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

12 December 2020

Molecular Mechanism of Insulin Resistance and Obesity

1 reference

12 December 2020

Insulin-induced adipocyte differentiation. Activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation.

1 reference

12 December 2020

Lipolysis in the absence of hormone-sensitive lipase: evidence for a common mechanism regulating distinct lipases

1 reference

12 December 2020

Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Adiponectin and Metabolic Syndrome

1 reference

12 December 2020

Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver

1 reference

12 December 2020

Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity.

1 reference

12 December 2020

Diabetes and cardiovascular disease. The Framingham study

1 reference

12 December 2020

Mouse insulin-responsive glucose transporter gene: characterization of the gene and trans-activation by the CCAAT/enhancer binding protein

1 reference

12 December 2020

Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity

1 reference

12 December 2020

Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy

1 reference

12 December 2020

Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction.

1 reference

12 December 2020

Predicting CHD risk in patients with diabetes mellitus

1 reference

12 December 2020

Insulinotropin PACAP potentiates insulin-stimulated glucose uptake in 3T3 L1 cells

1 reference

12 December 2020

10.1007/S00125-006-0269-5

Identifiers

DOI

1 reference

7 November 2017

1 reference